University of Vermont

College of Medicine

Vermont Cancer Center

trials_gyno.html

Gynecological Cancer Clinical Trials

The Vermont Cancer Center has many trials specifically focused on gynecological cancer research.

Status: Active - Recruiting
Study Title:
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC# 704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Purpose: This randomized phase III trial is studying giving carboplatin, paclitaxel and gemcitabine together with or without bevacizumab after surgery to see how well it works in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer
ClinicalTrials.gov Identifier: NCT00565851
Primary/Site/Co Investigator: Cheung Wong, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT00565851?term=GOG+0213&rank=1
Institution Number: 99-65 GOG 0213
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of Uterine Corpus
Purpose: This randomized phase II trial is studying radiation therapy and cisplatin to see how well they work compared with radiation therapy alone in treating patients with recurrent endometrial cancer.
ClinicalTrials.gov Identifier: NCT00492778
Primary/Site/Co Investigator: Cheung Wong, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT00492778?term=GOG+0238&rank=1
Institution Number: 99-65 GOG 0238
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
GOG-0260 A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (Sponsor: GOG, IND#110072)
Purpose: This phase II trial is studying the side effects of giving elesclomol sodium together with paclitaxel and to see how well it works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
ClinicalTrials.gov Identifier: NCT00888615
Primary/Site/Co Investigator: Cheung Wong, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT00888615?term=GOG-0260&rank=1
Institution Number: M11-156
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
GOG-0225: Can diet and physical activity modulate Ovarian, fallopian tube and primary peritoneal cancer progression-free survival?
Purpose: This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously treated stage II, stage III, or stage IV ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
ClinicalTrials.gov Identifier: NCT00719303
Primary/Site/Co Investigator: Cheung Wong, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://clinicaltrials.gov/show/NCT00719303
Institution Number: M13-193
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: GOG-3004/AstraZeneca SOLO1: A Randomized Double-Blind, Placebo-Controlled Phase III Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO stage III-IV) Ovarian Cancer Following First Line Platinum Therapy
Purpose: This study is for patients diagnosed with ovarian cancer (including patients with primary peritoneal and / or fallopian tube cancer).  To participate in this study, patients will be tested for a specific type of genetic mutation in the BRCA genes.  A mutation is a change in the deoxyribonucleic acid (DNA) which affects how some processes in the body work.   This study is for patients who had an improvement in their cancer (response) following first line platinum based chemotherapy.  This study is being carried out to see if a new treatment being tested, called olaparib, is effective in treating their ovarian cancer and preventing it coming back as quickly as it could otherwise do without any medication.  The current medical practice in their situation is not to take further medications until the cancer comes back. 
ClinicalTrials.gov Identifier: NCT01844986
Primary/Site/Co Investigator: Cheung Wong, MD
Contact: Jennifer Holmes (802) 847-3453
Information: https://clinicaltrials.gov/ct2/show/NCT01844986?term=d0818c00001&rank=1
Institution Number: M14-187
Protocol Research Type: Industry
Status: Active - Recruiting
Study Title: GOG-0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC #91485) versus Pacllitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, stage IVB, or Recurrent Endometrial Cancer
Purpose: The purpose of this study is to find out if the drug combination of paclitaxel, carboplatin and metformin works better than paclitaxel and carboplatin alone in treating advanced or recurrent endometrial (uterine) cancer and to find out what side effects are caused by treatment with these drugs.
ClinicalTrials.gov Identifier: NCT02065687
Contact: Jennifer Holmes (802) 847-3453
Information: https://clinicaltrials.gov/ct2/show/NCT02065687?term=gog-0286b&rank=1
Institution Number: M14-461
Protocol Research Type: Cooperative Group (GOG)

Last modified August 26 2014 10:50 AM